Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-12002217

Enrollment

Unknown

Registered

2012-05-31

Start date

2006-06-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B virus-related cirrhosis

Interventions

Compensated cirrhosis group:entecavir 0.5 mg once daily

Decompensated cirrhosis group:entecavir 0.5 mg once daily

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients were nucleoside-naive prior to entecavir treatment, and had serum HBV DNA =500 copies/mL .

Exclusion criteria

Exclusion criteria: Exclusion criteria included: co-infection with HIV, hepatitis A, hepatitis C, hepatitis delta or hepatitis E virus; and active alcohol abuse or dependence. Women who were pregnant or breastfeeding were also excluded.

Design outcomes

Primary

Measure	Time frame
HBV DNA;HBeAg seroconversion;Child-Pugh score;disease progression;Histological improvement;	—

Secondary

Measure	Time frame
normalization of serum alanine aminotransferase;liver function;	—

Countries

China

Contacts

Public ContactWang Jiangbin

zrlwangjb@medmail.com.cn+86 0431 84995303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026